Drugs - real world outcomes · 2026
Evaluation of Effectiveness and Safety of Telmisartan and Amlodipine Fixed-Dose Combination in Indian Patients with Hypertension: TACT-India Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Das Ashok Kumar, Tiwaskar Mangesh, Abdullakutty Jabir, Pande Arindam, Kumar Viveka, Francis Febin, Zalte Nitin, Sugumaran Amarnath, Sawant Sandesh, Mohanasundaram Senthilnathan
Аннотация
BACKGROUND: Hypertension is a major global health burden associated with significant cardiovascular morbidity and mortality. Fixed-dose combinations (FDC) may improve blood pressure (BP) control and prevent associated complications. This study aimed to evaluate the effectiveness and safety of telmisartan and amlodipine FDC in Indian patients with hypertension.
METHODS: This prospective, multicenter (n = 982), observational, real-world study enrolled patients aged ≥ 18 years diagnosed with hypertension and prescribed telmisartan and amlodipine FDC. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to 8 weeks. Safety was assessed on the basis of the incidence of adverse events reported by patients or observed by clinicians.
RESULTS: Out of 8541 individuals screened, 6232 were enrolled. A significant reduction in mean SBP was observed, decreasing from 155.12 mmHg at baseline to 135.96 mmHg at week 8 (P < 0.0001). Similarly, a reduction in mean diastolic blood pressure (DBP) was seen from 104.47 mmHg at baseline to 88.45 mmHg at week 8 (P < 0.0001). Around 70% of patients achieved the target BP (< 140/90 mmHg). Within the context of the study design, the physicians' global efficacy assessment suggested that 51.35% were extremely satisfied and 48.01% were satisfied with the treatment outcomes. Similarly, the tolerability assessment indicated that 52.95% of physicians were extremely satisfied and 45.84% were satisfied, while only a small proportion (0.54-0.64%) reported neutrality.
CONCLUSIONS: Treatment with telmisartan and amlodipine FDC demonstrated significant antihypertensive effectiveness and was well-tolerated in the real-world among Indian patients with hypertension.
METHODS: This prospective, multicenter (n = 982), observational, real-world study enrolled patients aged ≥ 18 years diagnosed with hypertension and prescribed telmisartan and amlodipine FDC. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to 8 weeks. Safety was assessed on the basis of the incidence of adverse events reported by patients or observed by clinicians.
RESULTS: Out of 8541 individuals screened, 6232 were enrolled. A significant reduction in mean SBP was observed, decreasing from 155.12 mmHg at baseline to 135.96 mmHg at week 8 (P < 0.0001). Similarly, a reduction in mean diastolic blood pressure (DBP) was seen from 104.47 mmHg at baseline to 88.45 mmHg at week 8 (P < 0.0001). Around 70% of patients achieved the target BP (< 140/90 mmHg). Within the context of the study design, the physicians' global efficacy assessment suggested that 51.35% were extremely satisfied and 48.01% were satisfied with the treatment outcomes. Similarly, the tolerability assessment indicated that 52.95% of physicians were extremely satisfied and 45.84% were satisfied, while only a small proportion (0.54-0.64%) reported neutrality.
CONCLUSIONS: Treatment with telmisartan and amlodipine FDC demonstrated significant antihypertensive effectiveness and was well-tolerated in the real-world among Indian patients with hypertension.